Careers
Investors
Contact
About
Our Platform
Pipeline & Programs
Pipeline Overview
See the 23andMe Therapeutics pipeline in full
23ME-00610
Clinical-stage therapeutic antibody designed to restore the immune system’s ability to kill cancer cells
23ME-01473
Clinical-stage antibody targeting ULBP6 to induce immune activation through dual mechanisms that may restore anti-tumor immunity.
Collaborations
News & Research
About Us
Our Platform
Pipeline & Programs
Overview
23ME-00610
23ME-01473
Collaborations
News & Research
Careers
Contact
Investors
Publications, Presentations, and News
News & Research
Select A Category
All Categories
23ME-00610
23ME-01473
Blog
Collaborations
Company
I&I
News
Press Release
Research
Select A Year
All Years
2024
2023
2022
2021
2018
2015
